Compare Natera Inc. Common Stock (NTRA) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs AT&T Inc. — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while AT&T Inc. trades at $23.26 (market cap $156.58B). The key difference: AT&T Inc. is far larger — about 2.7× Natera Inc. Common Stock's market cap, and AT&T Inc. pays a 4.86% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and AT&T Inc. for 118 Days on average.
| NTRA | T | |
|---|---|---|
Market Cap | $57.03B | $156.58B |
Volume | 1,131,157 | 46,597,672 |
Sector | Health | Media |
52-Week High | $425.64 | $29.10 |
52-Week Low | $179.42 | $20.49 |
Typical Hold Time | 0 Days | 118 Days |
Enterprise Value | $56.18B | $301.90B |
Dividend Yield | — | 4.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
AT&T (T) trades at $22.86, up 1.65% today, showing strong fundamental performance with a low P/E of 7.54 and robust profitability metrics including 16.94% net margin. The company has beaten earnings estimates for three consecutive quarters and maintains solid cash flow generation of $15.12B in 2025. Technical indicators show mixed signals with bearish moving averages but bullish oscillators, while analyst consensus remains divided with a $27.39 price target.
The stock presents value investment characteristics with attractive valuation multiples and consistent dividend payments. Key opportunities include fiber expansion initiatives and wireless growth, while risks center on heavy debt load and competitive pressures. The current price near support levels offers potential upside to analyst targets, though technical weakness requires monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
